# SYS6090 Combination Therapy in Advanced Lung Cancer

Source: https://onco.cc/trials/nct07472647/  
OnCo record `nct07472647` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of pemetrexed, paclitaxel / nab-paclitaxel, docetaxel, bevacizumab and other drugs in lung cancer, run by Shanghai JMT-Bio Inc., not yet recruiting.

## Summary

SYS6090 Combination Therapy in Advanced Lung Cancer is a phase 1/2, interventional study registered as NCT07472647 by Shanghai JMT-Bio Inc., with a registry enrolment figure of 596 participants, started 2026-02-28 and due to reach its primary completion in 2029-02-28. Interventions recorded: SYS6090 + pemetrexed + platinum-based chemotherapy; SYS6090 + paclitaxel + platinum-based chemotherapy; SYS6090 + docetaxel; SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapy; SYS6090 + SYS6010; SYS6090 + etoposide + platinum-based chemotherapy; SYS6090 + chemotherapy or other anticancer therapy. Conditions listed: Non-Small Cell Lung Cancer; Small Cell Lung Cancer. Primary outcome: Dose-Limiting Toxicity (DLT) (Phase Ib); Adverse Events (AEs) (Phase Ib); Objective response rate (ORR) (Phase II). Lung eligibility wording from the registry: "Histologically or cytologically confirmed unresectable locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-small cell lung cancer (NSCLC) according to the AJCC/UICC Cancer Staging System, 8th edition, or extensive-stage small cell lung cancer (SCLC), not amenable to curative surgical res". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07472647
- Phase: 1/2
- Setting: A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Efficacy of SYS6090 in Combination With Other Therapies in Participants With Advanced Lung Cancer
- Sponsor: Shanghai JMT-Bio Inc.
- Enrolled: 596

## Sources

- ClinicalTrials.gov NCT07472647: https://clinicaltrials.gov/study/NCT07472647

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Etoposide](https://onco.cc/drugs/etoposide/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [SYS6010](https://onco.cc/drugs/sys6010/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07472647.json